SCHEMBL5137690

SCHEMBL5137690

CCCCn1c(CN(CC=Cc2cc(OC)cc(OC)c2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.49
HTR2A P28223 3/20 0.41
HTR2C P28335 3/20 0.41
HTR2B P41595 3/20 0.41
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
F2R P25116 2/20 0.37
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137687 1.00 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5136596 0.89 C5AR1 (0.47) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5136593 0.89 C5AR1 (0.47) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5135160 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5135157 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5137286 0.87 C5AR1 (0.52) C5AR1PPARGPPARASMN1; SMN2TDP1
SCHEMBL5137287 0.87 C5AR1 (0.52) C5AR1PPARGPPARASMN1; SMN2TDP1
SCHEMBL5136237 0.87 C5AR1 (0.55) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5136867 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BPPARG
SCHEMBL5136549 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed